| Nothing's Wrong With The Offside Law...
A little health warning to begin this latest installment of refereeing analysis: West Ham fans, you may wish to read on, but do so with caution. Reading this week's Ref365 involves reliving a painful weekend moment, when the referee in the game at St. James' Park cost you points. This may lead to indigestion, but whatever you do, do not resort to usual methods of curing indigestion, heartburn and trapped wind. Rennie will not help. I visited the Rennie website to check what symptoms one would expect to have if suffering an ailment which said medication can relieve and I found one such symptom is 'acid taste in the mouth'. I would suggest that Newcastle v West Ham on Saturday would certainly have left a bitter taste in the mouth of all Hammers this weekend. Funnily enough, 'pain in the side' is also listed as a symptom, which I suppose is what supporters of the Toon may have developed, shortly before those sides indeed split through the general mirth and enjoyment Mr Rennie's performance may have invoked from a Geordie perspective.
Baton Rouge General first to have treatment technology
Baton Rouge General Medical Center says it's the first and only hospital in Louisiana to have a new technology that allows outpatient treatment for Barrett's esophagus, a precancer of the esophagus caused by chronic heartburn or gastroesophageal reflux disease. The technology that makes this possible is HALO360 from California-based BARRX Medical, a medical device company. BARRX has designated Baton Rouge General, which will teach other hospitals how to conduct the procedure, as a "Center of Excellence." Treatment options have been limited for Barrett's, which can lead to a dangerous type of cancer called esophageal adenocarcinoma, currently the most rapidly rising cancer in the United States affecting more than 3 million adults.
CONTINUED BELOW
.
Abbott To Initiate First Study To Evaluate XIENCE(TM) V Everolimus ...
Abbott today announced plans to initiate the world's first drug-eluting stent clinical trial solely in women. The SPIRIT WOMEN trial will aim to increase understanding of how heart disease affects women, and will assess the performance of the XIENCE(TM) V Everolimus Eluting Coronary Stent System in women with previously untreated coronary artery lesions.
Each year, more women than men die of cardiovascular disease (CVD), yet women receive only 33 percent of angioplasties, stents and bypass surgeries; 28 percent of implantable defibrillators; and 36 percent of open-heart surgeries(1). This may be attributed to the fact that diagnosis of CVD in women is more challenging than in men, as women typically exhibit different symptoms than men because their symptoms are more gradual and subtle.
|
